Jentashapir Journal of Health Research

Published by: Kowsar

Skin as a Psychoneuroendocrine Immunology Microcosm: The New Frontier of Low Dose Therapy With Cytokines and Growth Factors in the Systemic Treatment of Chronic Autoimmune Inflammatory Diseases in Dermatology

Torello Lotti 1 , 2 , 3 , * , Tatiana Rivkina 4 and Massimo Fioranelli 5
Authors Information
1 Department of Dermatology, University of Rome “Guglielmo Marconi”, Rome, Italy
2 Institute of Dermatology LifeCronos, Florence, Italy
3 World Health Academy Foundation, Zurich, Switzerland
4 Private Practitioner, Rome, Italy
5 Physiology Department, University B.I.S., Group of Institutions, Punjab Technical University, Punjab, India
Article information
  • Jentashapir Journal of Health Research: April 01, 2016, 7 (2); e31875
  • Published Online: April 16, 2016
  • Article Type: Review Article
  • Received: July 28, 2015
  • Accepted: August 26, 2015
  • DOI: 10.17795/jjhr-31875

To Cite: Lotti T, Rivkina T, Fioranelli M. Skin as a Psychoneuroendocrine Immunology Microcosm: The New Frontier of Low Dose Therapy With Cytokines and Growth Factors in the Systemic Treatment of Chronic Autoimmune Inflammatory Diseases in Dermatology, Jentashapir J Helath Res. 2016 ;7(2):e31875. doi: 10.17795/jjhr-31875.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnote
References
  • 1. Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2010; 125(2 Suppl 2)-72[DOI][PubMed]
  • 2. Bacchus W, Aubel D, Fussenegger M. Biomedically relevant circuit-design strategies in mammalian synthetic biology. Mol Syst Biol. 2013; 9: 691[DOI][PubMed]
  • 3. Ader R, Cohen N. Psychoneuroimmunology: conditioning and stress. Annu Rev Psychol. 1993; 44: 53-85[DOI][PubMed]
  • 4. Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet. 1995; 345(8942): 99-103[PubMed]
  • 5. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012; 37(1): 137-62[DOI][PubMed]
  • 6. Ngoc PL, Gold DR, Tzianabos AO, Weiss ST, Celedon JC. Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol. 2005; 5(2): 161-6[PubMed]
  • 7. Lourenco EV, La Cava A. Cytokines in systemic lupus erythematosus. Curr Mol Med. 2009; 9(3): 242-54[PubMed]
  • 8. Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol. 2010; 125(2 Suppl 2)-32[DOI][PubMed]
  • 9. Dainichi T, Hanakawa S, Kabashima K. Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity. J Dermatol Sci. 2014; 76(2): 81-9[DOI][PubMed]
  • 10. Rawles ME. Origin of pigment cells from the neural crest in the mouse embryo. Physiol Zool. 1947; 20(3): 248-66[PubMed]
  • 11. Burnett AF, Biju PG, Lui H, Hauer-Jensen M. Oral interleukin 11 as a countermeasure to lethal total-body irradiation in a murine model. Radiat Res. 2013; 180(6): 595-602[DOI][PubMed]
  • 12. Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA, et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology. 2014; 146(1): 210-221 e13[DOI][PubMed]
  • 13. Forster K, Goethel A, Chan CW, Zanello G, Streutker C, Croitoru K. An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology. 2012; 143(5): 1298-307[DOI][PubMed]
  • 14. Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 2013; 65(6): 822-32[DOI][PubMed]
  • 15. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013; 447(1-2): 75-93[DOI][PubMed]
  • 16. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DJ, Lee DH, et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev. 2012; 33(3): 378-455[DOI][PubMed]
  • 17. Biancotto A, Wank A, Perl S, Cook W, Olnes MJ, Dagur PK, et al. Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS One. 2013; 8(12)[DOI][PubMed]
  • 18. Gariboldi S, Palazzo M, Zanobbio L, Dusio GF, Mauro V, Solimene U, et al. Low dose oral administration of cytokines for treatment of allergic asthma. Pulm Pharmacol Ther. 2009; 22(6): 497-510[DOI][PubMed]
  • 19. D’Amico L, Ruffini E, Ferracini R, Roato I. Low dose of IL-12 stimulates T cell response in cultures of PBMCs derived from non small cell lung cancer patients. J Cancer Ther. 2012; 3(4): 337-42[DOI]
  • 20. Cardani D, Dusio GF, Luchini P, Sciarabba M, Solimene U, Rumio C. Oral administration of interleukin-10 and anti-IL-1 antibody ameliorates experimental intestinal inflammation. Gastroenterol Res. 2013; 6(4): 124-33[DOI]
  • 21. Radice E, Miranda V, Bellone G. Low-doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. Int Immunopharmacol. 2014; 19(1): 66-73[DOI][PubMed]
  • 22. Roberti ML, Ricottini L, Capponi A, Sclauzero E, Vicenti P, Fiorentini E, et al. Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. J Biol Regul Homeost Agents. 2014; 28(1): 133-9[PubMed]
  • 23. Barygina V, Becatti M, Lotti T, Moretti S, Taddei N, Fiorillo C. Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin. J Dermatol Sci. 2015; 79(2): 163-70[DOI][PubMed]
  • 24. Lotti T, Hercogova J, Wollina U, Chokoeva AA, Zarrab Z, Gianfaldoni S, et al. Vitiligo: successful combination treatment based on oral low dose cytokines and different topical treatments. J Biol Regul Homeost Agents. 2015; 29(1 Suppl): 53-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments